GlobeNewswire Inc | May 20, 2021 08:00AM EDT

May 20, 2021

REDWOOD CITY, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced thatAnish Bhatnagar, M.D., Chief Executive Officer, will present a corporate overview at the Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 at 1:15 PM Eastern Time.

A live audio webcast and replay of the presentation will be available in the Investors section on the Companys website atwww.soleno.life.

AboutSoleno Therapeutics, Inc.Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The companys lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase 3 clinical development program. For more information, please visit www.soleno.life.

Corporate Contact:Brian RitchieLifeSci Advisors, LLC212-915-2578